N-(2-alkylaminoethyl)-4-(1,2,4-oxadiazol-5-yl)piperazine-1-carboxamides as highly potent smoothened antagonists
Ester Muraglia(IRBM Science Park), Philip Jones(The University of Texas MD Anderson Cancer Center), Caterina Torrisi(IRBM Science Park), Gabriella Dessole(IRBM Science Park), Michael Rowley(IRBM Science Park), Jesus M. Ontoria(IRBM Science Park), Laura Llauger Bufi(IRBM Science Park), Maria Cecilia Palumbi(IRBM Science Park), Massimiliano Fonsi(IRBM Science Park), Alberto Bresciani(University of Bergamo), Claudio Giuliano(IRBM Science Park), Danila Branca(IRBM Science Park), Christian Steinkühler, Edith Monteagudo(IRBM Science Park)
Cited by 25
Related Papers
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
|Nature Medicine|2023|372
Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors
|Nature Medicine|2006|339
The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
|Cancer Research|2015|275
Adipogenesis of skeletal muscle fibro/adipogenic progenitors is affected by the WNT5a/GSK3/β-catenin axis
|Cell Death and Differentiation|2020|149